- About us
- Company details
BM Diagnostics is an Italian MedTech and healthtech company focused on making prevention and diagnostics more accessible, decentralized and closer to people.
The company develops innovative solutions that combine diagnostic technologies, biomarker testing, digital health and artificial intelligence, with the objective of supporting earlier health assessment and creating more accessible pathways between individuals and healthcare professionals.
BM Diagnostics is building a scalable B2B and B2B2C healthcare ecosystem, designed to operate across different healthcare environments, including pharmacies, clinics, primary care centers, diagnostic facilities, healthcare providers, corporate health programs and other community-based settings.
At the center of the current commercial offering is ProXcare™, an integrated platform designed to enable healthcare organizations to introduce rapid diagnostic and preventive services. ProXcare™ combines diagnostic equipment, a growing portfolio of biomarker-based testing programs, professional training, operational support and communication tools into a flexible service model.
The ProXcare™ portfolio addresses multiple areas of everyday health and prevention, including inflammation and infection, metabolic health, wellness, women's and hormonal health, kidney health, screening and family care. The modular structure allows healthcare partners to select and expand services according to their specific market, patient population and regulatory environment.
BM Diagnostics' business model is designed to create value for both healthcare providers and the people they serve. By introducing accessible diagnostic services, healthcare organizations can expand their offering, strengthen professional engagement, encourage preventive behaviors and create opportunities for continuous monitoring and follow-up.
Alongside its current ecosystem, BM Diagnostics is developing its next generation of cardiovascular diagnostic technologies. HeartBeat Test™ is being developed as a quantitative, self-diagnostic cardiovascular IVD platform for biomarker testing, while TestWise™ is being developed as a digital and AI-enabled platform designed to support cardiovascular risk assessment and longitudinal monitoring. Both technologies are currently under development and regulatory preparation and are intended to become future components of the broader BM Diagnostics ecosystem.
The company's innovation strategy combines biotechnology, medical diagnostics, digital technologies and AI, with a strong focus on validation, regulatory development and real-world healthcare applications.
BM Diagnostics is now pursuing an international expansion strategy and is seeking distributors, healthcare providers, pharmacy and healthcare networks, diagnostic organizations, strategic partners and pilot sites interested in deploying innovative decentralized prevention and diagnostic services.
Our vision is simple: to innovate prevention and bring diagnostics closer to people.
Year of establishment:
2023
Number of employees:
UP TO 2 EMPLOYEES
Annual turnover:
Not available
Reference year of turnover:
2024
Export turnover:
0
Activities:
Manufacture of other pharmaceutical preparations
Wholesale of medical and orthopaedic goods
Non-specialised retail sale
Research and experimental development on biotechnology
- Videos
- Catalogue
No videos uploaded
No documents uploaded
- Contact Information
- Business Proposals
Company:
BM DIAGNOSTICS SOCIETA' A RESPONSABILITA' LIMITATA SEMPLIFICATA
Web site:
Address:
V. S. MARGHERITA 21
City:
CANTIANO (PU)
Zip Code:
61044
Tag:
No business proposals uploaded
- Map
ProXcare™ – Advanced Prevention & Diagnostic Healthcare Ecosystem
ProXcare™ is an innovative B2B healthcare ecosystem designed to bring prevention, rapid diagnostics and health monitoring closer to people. The platform enables healthcare organizations and community-based healthcare providers to introduce accessible diagnostic services through an integrated combination of technology, biomarker-based testing, professional training and ongoing operational support.
Designed as a flexible and scalable solution, ProXcare™ can be deployed across different healthcare environments, including pharmacies, clinics, primary care centers, diagnostic facilities, healthcare networks, corporate health programs and other community-based healthcare settings, subject to local regulatory requirements.
The ecosystem provides access to a growing portfolio of rapid diagnostic programs covering key areas of preventive healthcare, including inflammation and infection, metabolic health, wellness, women's and hormonal health, kidney health, screening, family care and general health monitoring.
ProXcare™ is designed to simplify the introduction of decentralized diagnostic services. Healthcare partners can access the necessary infrastructure, diagnostic portfolio, training and operational support through a single integrated model, allowing them to expand their healthcare offering while maintaining a consistent and professional service experience.
The platform creates value throughout the healthcare journey. Instead of a single interaction, a diagnostic service can become the starting point for professional consultation, prevention, follow-up and ongoing health monitoring. This approach can strengthen engagement with individuals while creating new sustainable service opportunities for healthcare organizations.
ProXcare™ follows a B2B and B2B2C business model, targeting healthcare providers, pharmacy and healthcare networks, diagnostic organizations, distributors, clinics, corporate health programs and strategic partners. The platform is designed to support both individual healthcare centers and larger multi-site deployments.
The ecosystem is also designed to evolve with BM Diagnostics' technology roadmap. The company is developing HeartBeat Test™, a quantitative self-diagnostic cardiovascular IVD technology, and TestWise™, a digital and AI-enabled platform for cardiovascular risk assessment and monitoring. These technologies are currently under development and regulatory preparation and are intended to become future components of the wider ProXcare™ ecosystem.
Through the combination of diagnostics, biotechnology, digital health and artificial intelligence, BM Diagnostics aims to create a new model of accessible and decentralized healthcare.
BM Diagnostics is seeking international distributors, healthcare organizations, strategic partners and pilot sites interested in deploying innovative prevention and diagnostic services and expanding access to decentralized healthcare.
Web site
https://bmdiagnostics.it
Documents
